Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study

J Infect. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.03.004. Epub 2022 Mar 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Hepatitis C* / drug therapy
  • Humans
  • Rifampin / therapeutic use
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents
  • Rifampin